Résumé
Clinical trials for lung cancer are needed to investigate new treatment or preventative options and to improve outcomes for patients with lung cancer. Times are changing; clinical researchers now are faced with the challenge of interpreting huge amounts of basic-science data and preclinical concepts. The challenge is to build the most appropriate trials to validate these hypotheses. Not only do potential therapeutic drugs need investigating, but with personalized medicine, biomarkers are vital to identify the patients who will respond to a certain therapy. Thus, clinical researchers must balance cost, the strength of basic-science and preclinical data, and feasibility when developing clinical trials. New clinical trial designs and more collaborations are possible solutions that are presented in this chapter.
langue originale | Anglais |
---|---|
titre | IASLC Thoracic Oncology |
Editeur | Elsevier |
Pages | 628-634.e2 |
ISBN (Electronique) | 9780323523578 |
ISBN (imprimé) | 9780323527835 |
Les DOIs | |
état | Publié - 1 janv. 2018 |
Modification externe | Oui |